Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Impact of Personality on Cognitive Aging: A Prospective Cohort Study.

Caselli RJ, Dueck AC, Locke DE, Henslin BR, Johnson TA, Woodruff BK, Hoffman-Snyder C, Geda YE.

J Int Neuropsychol Soc. 2016 Aug;22(7):765-76. doi: 10.1017/S1355617716000527. Epub 2016 Jun 27.

PMID:
27346168
2.

Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data.

Basch E, Dueck AC.

Expert Opin Drug Discov. 2016 Aug;11(8):753-8. doi: 10.1080/17460441.2016.1193148. Epub 2016 Jun 16.

PMID:
27310432
3.

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr.

J Natl Cancer Inst. 2016 Apr 20;108(8). pii: djw037. doi: 10.1093/jnci/djw037. Print 2016 Aug.

PMID:
27098150
4.

Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma.

Mangold AR, Skinner R, Dueck AC, Sekulic A, Pockaj BA.

Dermatol Surg. 2016 May;42(5):646-52. doi: 10.1097/DSS.0000000000000702.

PMID:
27082057
5.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.

Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA.

Cancer. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12.

PMID:
27070130
6.

Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.

Basch E, Rogak LJ, Dueck AC.

Clin Ther. 2016 Apr;38(4):821-30. doi: 10.1016/j.clinthera.2016.03.011. Epub 2016 Apr 2.

PMID:
27045992
7.

Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, Schrag D, Basch E; National Cancer Institute PRO-CTCAE Study Group.

Health Qual Life Outcomes. 2016 Feb 19;14:24. doi: 10.1186/s12955-016-0426-6.

8.

MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.

Lakshminarayanan V, Supekar NT, Wei J, McCurry DB, Dueck AC, Kosiorek HE, Trivedi PP, Bradley JM, Madsen CS, Pathangey LB, Hoelzinger DB, Wolfert MA, Boons GJ, Cohen PA, Gendler SJ.

PLoS One. 2016 Jan 20;11(1):e0145920. doi: 10.1371/journal.pone.0145920. eCollection 2016.

9.

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.

Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, Geyer HL, McCallister A, Cotter M, Van Husen B, Harrison CN, Mesa RA.

Cancer. 2016 Feb 1;122(3):477-85. doi: 10.1002/cncr.29753. Epub 2015 Dec 15.

PMID:
26670597
10.

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D.

J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7. Erratum in: J Clin Oncol. 2016 Jun 20;34(18):2198.

PMID:
26644527
11.

Regional recurrence in the era of sentinel lymph node biopsy.

Linnaus ME, Dueck AC, Kosiorek HE, Gray RJ, Wasif N, Northfelt DW, Anderson KS, McCullough AE, Wong WW, Halyard MY, Patel SH, Pockaj BA.

Am J Surg. 2015 Dec;210(6):1155-60; discussion 1160-1. doi: 10.1016/j.amjsurg.2015.09.001. Epub 2015 Sep 28.

PMID:
26601646
12.

Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma.

Hu LS, Ning S, Eschbacher JM, Gaw N, Dueck AC, Smith KA, Nakaji P, Plasencia J, Ranjbar S, Price SJ, Tran N, Loftus J, Jenkins R, O'Neill BP, Elmquist W, Baxter LC, Gao F, Frakes D, Karis JP, Zwart C, Swanson KR, Sarkaria J, Wu T, Mitchell JR, Li J.

PLoS One. 2015 Nov 24;10(11):e0141506. doi: 10.1371/journal.pone.0141506. eCollection 2015.

13.

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA.

J Clin Oncol. 2016 Jan 10;34(2):151-9. doi: 10.1200/JCO.2015.62.9337. Epub 2015 Nov 23.

PMID:
26598745
14.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23.

PMID:
26598744
15.

The relationship among gastroparetic symptoms, quality of life, and gastric emptying in patients referred for gastric emptying testing.

DiBaise JK, Patel N, Noelting J, Dueck AC, Roarke M, Crowell MD.

Neurogastroenterol Motil. 2016 Feb;28(2):234-42. doi: 10.1111/nmo.12718. Epub 2015 Nov 7.

PMID:
26547484
16.

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Geyer HL, Dueck AC, Scherber RM, Mesa RA.

Mediators Inflamm. 2015;2015:284706. doi: 10.1155/2015/284706. Epub 2015 Oct 11. Review.

17.

Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying.

Dibaise JK, Islam RS, Dueck AC, Roarke MC, Crowell MD.

Neurogastroenterol Motil. 2016 Feb;28(2):196-205. doi: 10.1111/nmo.12709. Epub 2015 Oct 28.

PMID:
26511077
18.

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.

Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, Cherbavaz D, Yoshizawa C, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV.

Breast Cancer Res. 2015 Oct 1;17(1):133. doi: 10.1186/s13058-015-0643-7.

19.

Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma.

Hu LS, Kelm Z, Korfiatis P, Dueck AC, Elrod C, Ellingson BM, Kaufmann TJ, Eschbacher JM, Karis JP, Smith K, Nakaji P, Brinkman D, Pafundi D, Baxter LC, Erickson BJ.

AJNR Am J Neuroradiol. 2015 Dec;36(12):2242-9. doi: 10.3174/ajnr.A4451. Epub 2015 Sep 10.

20.

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA.

Oncotarget. 2015 Sep 22;6(28):26483-93. doi: 10.18632/oncotarget.4494.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk